Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms.
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control
D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids